Glembatumumab vedotin clinical trials
Also written CDX-011 and CR011-vcMMAE.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How each study uses glembatumumab vedotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 5
National Cancer Institute (NCI) (3) · Celldex Therapeutics (3) · CuraGen Corporation (2) · PrECOG, LLC. (1) · University of Virginia (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses glembatumumab vedotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast CancerWithdrawnEarly Phase 1University of VirginiaNCT03473691Written as Glembatumumab VedotinHow we know
- Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory OsteosarcomaCompletedPhase 2National Cancer Institute (NCI)NCT02487979Written as Glembatumumab VedotinHow we know
- Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal MelanomaCompletedPhase 2National Cancer Institute (NCI)NCT02363283Written as Glembatumumab VedotinHow we know
- A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced MelanomaTerminatedPhase 2Celldex TherapeuticsNCT02302339Written as glembatumumab vedotinHow we know
- Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the LungTerminatedPhase 1/2PrECOG, LLC.NCT02713828Written as Phase I: Glembatumumab VedotinHow we know
- Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast CancerCompletedPhase 2Celldex TherapeuticsNCT01997333Written as CDX-011How we know
- Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryWithdrawnPhase 1/2National Cancer Institute (NCI)NCT03326258Written as Glembatumumab VedotinHow we know
- A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast CancerCompletedPhase 2Celldex TherapeuticsNCT01156753Written as CDX-011How we know
- Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast CancerCompletedPhase 1/2CuraGen CorporationNCT00704158Written as CR011-vcMMAEHow we know
- A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV MelanomaCompletedPhase 1/2CuraGen CorporationNCT00412828Written as CR011-vcMMAEHow we know
Codes
What other systems call glembatumumab vedotin · ClinicalTrials.gg INT005673
- MeSH (NLM) C551271glembatumumab vedotinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 1568H6A58UGLEMBATUMUMAB VEDOTINConfirmed FDA, NLM, Wikidata
- Wikidata Q3771944glembatumumab vedotinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C78449Glembatumumab VedotinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C551271 | glembatumumab vedotin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 1568H6A58U | GLEMBATUMUMAB VEDOTIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q3771944 | glembatumumab vedotin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C78449 | Glembatumumab Vedotin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.